Viking Therapeutics' Phase 3 Trial: High Stakes
Business & Finance News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Viking Therapeutics VK2735, a dual GLP-one slash GIP agonist for weight loss, is in phase three trials, with data expected in the next eighteen months. If successful, it could rival Eli Lillys Zepbound and capture significant market share in a growing space. However, the biotech industry is risky, with most companies failing to deliver. Investors must weigh the potential rewards against the high stakes and bankruptcy risks.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/3675c8c8e2bfa16b